Loss of Myosin Prognostic for Colorectal Cancer Recurrence
By LabMedica International staff writers Posted on 22 Jan 2018 |
Image: The crystal structure of nucleotide-free myosin V with essential light chain (Photo courtesy of Wikimedia Commons).
Loss of the protein Myosin Vb in colorectal cancer (CRC) patients has been identified as a strong prognostic factor for recurrence of the disease.
Early detection and classification of CRC is of great importance, since not all Stage II patients benefit from chemotherapy. There are few known prognostic markers for CRC so that many patients suffer needlessly from side effects of the chemotherapy without having real benefits. Members of the Myosin family, proteins recognized to have a major role in trafficking and polarization of cells, have recently been reported to be closely associated with several types of cancer and might thus serve as potential prognostic markers in the context of CRC.
Myosin V is an unconventional myosin motor, which translocates along actin filaments traveling towards the barbed end of the filaments. Myosin V is involved in the transport of cargo (e.g. RNA, vesicles, organelles, mitochondria) from the center of the cell to the periphery, but has been furthermore shown to act like a dynamic tether, retaining vesicles and organelles in the actin-rich periphery of cells.
Investigators at the University of Luxembourg (Belvaux) used a previously established meta-analysis of publicly available gene expression data to analyze the expression of different members of the Myosin V family, namely MYO5A, 5B, and 5C, in CRC. Using laser-microdissected material as well as tissue microarrays from paired human CRC samples, they validated both RNA and protein expression of Myosin Vb (MYO5B) and its known adapter proteins (RAB8A and RAB25) in an independent patient cohort. Finally, they assessed the prognostic value of both MYO5B and its adapter-coupled combinatorial gene expression signatures.
Results revealed methylation-independent loss of MYO5B expression in CRC that matched disease progression. Significantly, CRC patients with low MYO5B expression displayed shorter overall, disease-, and metastasis-free survival, a trend that was further reinforced when RAB8A expression was also taken into account. These findings identified MYO5B as a powerful prognostic biomarker in CRC, especially in early stages (stages I and II), which could help stratifying patients with stage II for adjuvant chemotherapy.
"The strength of the study lies in the concerted effort and the interdisciplinary approaches, involving bioinformatics and state-of-the-art experimental techniques. Especially the financial support from the Fondation Cancer has been crucial for the successful completion of our biomarker projects," said senior author Dr. Elisabeth Letellier, research associate in life sciences at the University of Luxemburg.
Related Links:
University of Luxembourg
Early detection and classification of CRC is of great importance, since not all Stage II patients benefit from chemotherapy. There are few known prognostic markers for CRC so that many patients suffer needlessly from side effects of the chemotherapy without having real benefits. Members of the Myosin family, proteins recognized to have a major role in trafficking and polarization of cells, have recently been reported to be closely associated with several types of cancer and might thus serve as potential prognostic markers in the context of CRC.
Myosin V is an unconventional myosin motor, which translocates along actin filaments traveling towards the barbed end of the filaments. Myosin V is involved in the transport of cargo (e.g. RNA, vesicles, organelles, mitochondria) from the center of the cell to the periphery, but has been furthermore shown to act like a dynamic tether, retaining vesicles and organelles in the actin-rich periphery of cells.
Investigators at the University of Luxembourg (Belvaux) used a previously established meta-analysis of publicly available gene expression data to analyze the expression of different members of the Myosin V family, namely MYO5A, 5B, and 5C, in CRC. Using laser-microdissected material as well as tissue microarrays from paired human CRC samples, they validated both RNA and protein expression of Myosin Vb (MYO5B) and its known adapter proteins (RAB8A and RAB25) in an independent patient cohort. Finally, they assessed the prognostic value of both MYO5B and its adapter-coupled combinatorial gene expression signatures.
Results revealed methylation-independent loss of MYO5B expression in CRC that matched disease progression. Significantly, CRC patients with low MYO5B expression displayed shorter overall, disease-, and metastasis-free survival, a trend that was further reinforced when RAB8A expression was also taken into account. These findings identified MYO5B as a powerful prognostic biomarker in CRC, especially in early stages (stages I and II), which could help stratifying patients with stage II for adjuvant chemotherapy.
"The strength of the study lies in the concerted effort and the interdisciplinary approaches, involving bioinformatics and state-of-the-art experimental techniques. Especially the financial support from the Fondation Cancer has been crucial for the successful completion of our biomarker projects," said senior author Dr. Elisabeth Letellier, research associate in life sciences at the University of Luxemburg.
Related Links:
University of Luxembourg
Latest Molecular Diagnostics News
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset